Sionna Therapeutics, Inc.
$42.64
▼
-1.96%
2026-04-21 09:25:01
www.sionnatx.com
NGM: SION
Explore Sionna Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.96 B
Current Price
$42.64
52W High / Low
$46.46 / $9.24
Stock P/E
—
Book Value
$6.86
Dividend Yield
—
ROCE
-28.32%
ROE
-31.79%
Face Value
—
EPS
$-1.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
—
Debt / Equity
2.83
Current Ratio
20.61
Quick Ratio
20.61
Forward P/E
-14.68
Price / Sales
—
Enterprise Value
$1.48 B
EV / EBITDA
-16.73
EV / Revenue
—
Rating
Strong Buy
Target Price
$49.11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Outlook Therapeutics, Inc. | $0.37 | — | $38.71 M | — | 246.27% | 118.61% | $3.39 / $0.16 | $-0.6 |
| 2. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 3. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 4. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
| 5. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
| 6. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 7. | Kyverna Therapeutics, Inc. | $11.25 | — | $600.17 M | — | -65.99% | -64.67% | $13.67 / $1.78 | $3.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -23.61 M | -23.8 M | -21.91 M | -19.66 M | -18.13 M |
| Net Profit | -20.44 M | -20.28 M | -18.07 M | -16.48 M | -15.85 M |
| EPS in Rs | -0.45 | -0.45 | -0.4 | -0.37 | -0.35 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -88.98 M | -70.56 M | -50.33 M | -41.37 M |
| Net Profit | -75.27 M | -61.69 M | -47.26 M | -40.24 M |
| EPS in Rs | -1.67 | -1.37 | -1.05 | -0.89 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 325.95 M | 185.75 M | 51.95 M | 87.37 M |
| Total Liabilities | 19.12 M | 349.46 M | 166.83 M | 157.29 M |
| Equity | 306.83 M | -163.71 M | -114.88 M | -69.92 M |
| Current Assets | 241.42 M | 150.99 M | 39.21 M | 83.83 M |
| Current Liabilities | 11.71 M | 10.42 M | 8.04 M | 8.25 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -66.3 M | -52.79 M | -43.7 M | -36.07 M |
| Investing CF | -118.75 M | -126.91 M | 27.35 M | -29.26 M |
| Financing CF | 205.71 M | 178.97 M | 0.03 M | 110.86 M |
| Free CF | -66.67 M | -52.81 M | -44.81 M | -37.94 M |
| Capex | -0.38 M | -0.03 M | -1.12 M | -1.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -22.01% | -30.52% | -17.45% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.